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Combination antiretroviral therapy and duration of
pregnancy
The European Collaborative Study and the Swiss Mother  Child HIV
Cohort Study
Objective: To assess the association between type and timing of initiation of antire-
troviral therapy in pregnancy and duration of pregnancy.
Design: Prospective study.
Methods: Data on 3920 mother±child pairs were examined (3015 mother±child pairs
from the European Collaborative Study and 905 from the Swiss Mother  Child HIV
Cohort Study). Factors examined included gestational age, antiretroviral therapy
during pregnancy, maternal CD4 count, viral load, illicit drug use (IDU) and mode of
delivery. Deliveries at less than 37 weeks were de®ned as premature.
Results: The prematurity rate was 17% and median gestational age 39 weeks. Twenty-
three per cent (896 of 3920) of women received antiretroviral therapy during preg-
nancy: 64% (573 of 896) zidovudine monotherapy, 24% (215) combination therapy
without protease inhibitors (PI) and 12% (108) combination therapy with PI. In
multivariate analysis, adjusted for maternal CD4 count and IDU, odds ratio (OR) of
prematurity was 2.60 [95% con®dence interval (CI), 1.43±4.75] and 1.82 (95% CI,
1.13±2.92) for infants exposed to combination therapy with and without a PI,
respectively, compared to no treatment. Exposure to monotherapy was not associated
with prematurity, but severe immunosuppression and IDU in pregnancy were. Women
on combination therapy from before pregnancy were twice as likely to deliver
prematurely as those starting therapy in the third trimester (OR, 2.17; 95% CI, 1.03±
4.58).
Conclusions: Pregnancy issues should be discussed when making decisions about
initiation of combination antiretroviral therapy for HIV-infected women. Elective
caesarean section to reduce vertical transmission at 36 weeks rather than 38 weeks
may be advisable in women on combination therapy with PI.
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Introduction
Risk of mother-to-child transmission of HIV-1 infec-
tion can be reduced by prophylactic antiretroviral
therapy during pregnancy, delivery and in the neonatal
period, elective caesarean section delivery and refrain-
ing from breastfeeding [1]. A combination of these
three interventions is now commonly used and trans-
mission rates as low as 1% have been achieved [2±4].
Increasing numbers of women are now taking combi-
nation therapy in pregnancy both in the USA and
Europe [5±7]. Current recommendations do not in-
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clude speci®c guidelines on the use of combination
therapy in pregnancy, instead providing general princi-
ples for the use of antiretrovirals in pregnancy [1,8].
However, questions remain regarding the potential
adverse effects of antiretroviral therapy in pregnancy.
Exposure to antiretroviral therapy in fetal or early life
has in rare cases been associated with mitochondrial
abnormalities [9], but causality is dif®cult to prove.
Although there is no evidence to date that exposure to
antiretroviral therapy in pregnancy is associated with
congenital abnormalities or later development of can-
cers [10,11], one child with extrahepatic biliary atresia,
one with congenital glaucoma and one intracerebral
haemorrhage at term were reported among 95 children
exposed to combined antiretroviral therapy in the Swiss
Cohort [5, C. Rudin, personal communication, 2000].
However, the number of exposed children and dura-
tion of follow-up are limited, and the effect of newer
drug combinations uncertain. Evidence is lacking
regarding the effect of antiretroviral therapy on preg-
nancy outcomes such as spontaneous abortions, still-
births or premature deliveries.
In the European Collaborative Study (ECS), prophy-
lactic zidovudine monotherapy was associated with a
decreased risk of low birthweight and prematurity in a
cohort of 2300 HIV-infected women [12], whereas in
the Swiss cohort, there was an increased risk of
premature deliveries in 37 women treated with two or
more antiretroviral agents [5]. To further explore the
relationship between type and timing of initiation of
antiretroviral therapy and prematurity, data from the
ECS and the Swiss cohorts were combined.
Methods
The Swiss Mother  Child HIV Cohort Study (Mo-
CHiV) and the ECS are prospective studies, using
similar protocols to follow-up infants born to HIV-
infected women. The ECS, set up in 1986, includes 26
centres in nine European countries [2,13]. The Swiss
study was formed in 1998 following a merger of the
Swiss Neonatal HIV Study and the Swiss Collaborative
HIV and Pregnancy Study, active since 1986 and 1989
respectively [4]. Informed consent is obtained, and
ethics approval has been granted.
Information is collected on type and timing of initiation
of antiretroviral therapy, maternal CD4 count and viral
load during pregnancy [14], mother's illicit drug use
and other socio-demographic variables, mode of deliv-
ery, gestational age and neonatal characteristics. Gesta-
tional age was con®rmed by ultrasound and reported to
the nearest completed week. Premature delivery was
de®ned as delivery before 37 weeks of gestation.
In the ECS, maternal viral load and CD4 count were
determined locally, with type of assay recorded. In the
Swiss study laboratory tests were carried out in dedi-
cated reference centres with quality control by the
Swiss HIV Cohort Study [14]. Most (79%) tests were
carried out within the third trimester or up to 2 weeks
after delivery, and where multiple tests were available
that nearest delivery was used. Assay types used were
Roche (Amplicor Monitor, version 1.0; Roche Diag-
nostic Systems, Basel, Switzerland), NASBA and Nu-
clisens (Organon Teknika, Oss, Holland); tests were
usually carried out on plasma samples, but occasionally
on stored serum samples [2]. For each combination of
sample type (i.e. plasma or serum) and assay type, the
median was calculated, which was used to create the
summary variable of HIV RNA copy number [2].
Where used as a continuous variable, RNA viral load
level was log transformed.
Univariate comparisons for categorized variables were
tested with ÷2 test or ÷2 test for linear trend. Logistic
regression was used to obtain odds ratios (OR) and
95% con®dence intervals (CI), both univariate and
adjusted for potential confounders. Analyses were
performed using SAS statistical software (version 6.12;
SAS Institute, Cary, North Carolina, USA).
The logistic regression analysis included the following
factors: maternal CD4 count (categorized into three
variables: , 200, 200±499, > 500 3 106 cells/l), illicit
drug use in pregnancy (Y/N) and type of antiretroviral
therapy in pregnancy [none, monotherapy, combina-
tion therapy without protease inhibitor (PI), combina-
tion therapy with PI]. We performed a total of ®ve
separate multivariate analyses: (1) for all mother±child
pairs with information on gestational age at delivery,
CD4 count, drug use and antiretroviral therapy; (2)
including all the variables in analysis (1), plus maternal
age (categorized into three variables: , 25 years, 25±
29 years, > 30 years) and parity (categorized into four
variables: 0, 1, 2, > 3); (3) repeat of analysis (1),
excluding all deliveries by elective caesarean section;
(4) repeat of analysis (1), using ECS data only and (5)
repeat of analysis (1), using MoCHiV data only. A
dummy variable was created to investigate the existence
of any signi®cant differences in prematurity between
the ECS and the MoCHIV cohorts in multivariate
analysis. The possibility of a differential treatment effect
on prematurity between cohorts was investigated using
an interaction term in multivariate analysis.
Results
By April 2000, 3920 mother±child pairs were available,
3015 in the ECS and 905 in MoCHiV. Prematurity
rates in the MoCHiV, 16% (132 of 836), and ECS,
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17% (476 of 2829), were similar, as was the distribution
of maternal and delivery characteristics. The prematur-
ity rate overall was 17% (Table 1) and median gesta-
tional age 39 weeks (range, 25±43 weeks). Thirty-one
per cent of infants (n  1215) were born since January
1995.
Less than a quarter (896 of 3920, 23%) of women had
received antiretroviral therapy during pregnancy,
mostly (573 of 896, 64%) zidovudine monotherapy
(Table 1). The majority of women received antiretro-
viral therapy as prophylaxis to reduce vertical transmis-
sion and were clinically and immunologically well at
the time of initiation. The 323 women taking combi-
nation therapy most commonly received zidovudine
plus lamivudine (132 cases, 41%). Other nucleoside
reverse transcriptase inhibitors (NRTIs) taken were
zalcitabine, didanosine, stavudine and abacavir. Nel®-
navir was the most frequently used PI, used in 64 of
108 (59%) PI-containing combination regimens.
Thirty-eight women (12%) took indinavir in pregnancy
and a few took saquinavir and ritonavir.
Maternal RNA viral load when categorized was not
associated with prematurity, with prematurity rates of
19% (27 of 142) and 21% (31 of 151) for mothers with
RNA viral load below and above the median respec-
tively (P  0.745). Simple linear regression analysis
(excluding women with elective caesarean section)
showed a slight negative association between gestational
age and log maternal RNA viral load (P  0.149). In
Table 2, prematurity rates for each treatment group are
presented, strati®ed by maternal CD4 count (in three
categories). There was a consistently higher prematurity
rate in the combination therapy with PI treatment
group compared with the no treatment and monother-
apy groups across the three immunological categories.
Maternal CD4 cell count, illicit drug use in pregnancy
and combination antiretroviral therapy in pregnancy
were individually signi®cantly related to prematurity
(Table 3). For example, prematurity rates were 22%
among infants born to women with CD4 cell counts
below 200 3 106 cells/l, 24% among those whose
mothers had actively used illicit drugs in pregnancy and
29% among those exposed to combination therapy
with a PI. A logistic regression analysis included 1444
mother±child pairs with information on maternal CD4
count, illicit drug use in pregnancy and antiretroviral
therapy, with premature delivery as the dependent
variable (Table 3). The characteristics of women with
and without information on all four variables were
similar. Maternal CD4 count was included in the
model rather than viral load, because HIV RNA copy
number was not strongly associated with gestational age
or prematurity in univariate analysis; and fewer than
Table 1. Maternal and delivery characteristics.
n %
Maternal age at delivery (n  3613)
, 25 years 1095 30
25±29 years 1110 40
> 30 years 1075 30
CD4 cell count (3 106 cells/l) (n  1510)
, 200 239 16
200±499 689 46
> 500 582 38
Viral load (RNA copy number) (n  530)
Undetectable 230 43
Below mediana 145 27
Above mediana 155 29
Illicit drug use in pregnancy (n  3407)
No 2577 76
Yes 830 24
Antiretroviral therapy in pregnancy (n  3920)
None 3024 77
Monotherapy 573 15
Combination therapy: no PI 215 5
Combination therapy: with PI 108 3
Timing of initiation of antiretroviral therapy (n  707)
Pre-pregnancy 111 16
First trimester 34 5
Second trimester 238 34
Third trimester 324 46
Premature delivery (n  3665)
No 3057 83
Yes 608 17
Elective caesarean section (n  3870)
No 2878 74
Yes 992 26
aFor assay and sample type. PI, protease inhibitor.
Table 2. Prematurity rates, by treatment in pregnancy, strati®ed by CD4 cell count.
Maternal CD4 cell count
, 200 3 106 cells/l 200±499 3 106 cells/l > 500 3 106 cells/l
, 37 weeks > 37 weeks , 37 weeks > 37 weeks , 37 weeks > 37 weeks
n (%) n (%) n (%) n (%) n (%) n (%)
No treatment 31 (23) 104 (77) 60 (15) 353 (85) 45 (12) 346 (88)
Monotherapy 11 (16) 56 (84) 20 (14) 125 (86) 13 (12) 96 (88)
Combination therapy without PI 3 (20) 12 (80) 16 (22) 56 (78) 8 (22) 28 (78)
Combination therapy with PI 4 (50) 4 (50) 8 (24) 25 (76) 5 (23) 17 (77)
PI, protease inhibitor.
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400 mother±child pairs would have been included in
the analysis, severely limiting its power.
Exposure to combination antiretroviral therapy in-
creased risk of premature delivery independent of
maternal CD4 count and illicit drug use. Infants
exposed to antiretroviral therapy with a PI were 2.6
times more likely to be born prematurely compared
with those unexposed, with a lower but signi®cantly
increased risk for those exposed to antiretroviral
therapy involving only NRTIs (Table 3). Exposure
to monotherapy was not signi®cantly associated with
duration of pregnancy. Severely immunocompromised
women (CD4 cell count , 200 3 106 cells/l) and
those actively using illicit drugs (mainly heroin or
methadone) were also signi®cantly more likely to
deliver before 37 weeks gestation. We repeated the
logistic regression analysis to include maternal age
and parity, which had no substantial impact on the
effect of antiretroviral therapy on risk of premature
delivery. As elective caesarean section is recom-
mended for HIV-infected women, we repeated the
analysis with the 974 women delivered vaginally or
by emergency caesarean section. The results were
substantially similar with a somewhat larger effect of
combination therapy on the risk of prematurity.
Analyses were also carried out for the ECS and
MoCHiV separately, with similar results. There was
no signi®cant difference between the two cohorts in
multivariate analysis [adjusted odds ratio (AOR),
1.05; 95% con®dence interval (CI), 0.73±1.51;
P  0.805], nor evidence that the effect of treatment
on prematurity differed by cohort. A re-parameter-
ized multivariate analysis including combination ther-
apy with a PI as baseline treatment group showed
that combination therapy without a PI did not differ
signi®cantly from combination therapy with a PI in
predicting prematurity (AOR, 0.70; 95% CI, 0.34±
1.42; P  0.323).
Prematurity rates by type and timing of antiretroviral
therapy are presented in Table 4. Although risk of
prematurity was always high among women treated
with combination therapy with PIs, it was greatest
where antiretroviral therapy was initiated before and
retained throughout pregnancy or started in the ®rst
trimester (16 of 40, 40%), compared with initiation of
antiretroviral therapy in the second and third trimesters
(10 of 56, 18%) (÷2  5.73, P  0.030). In logistic
regression analysis, women on combination therapy
(with or without PIs) from before pregnancy were
twice as likely to deliver prematurely as those who
started in the third trimester (OR, 2.17; 95% CI,
1.03±4.58; P  0.043).
To further investigate how treatment regimen was
associated with gestational age, the cumulative distribu-
tion of gestational age at delivery by treatment group
was plotted, excluding elective caesarean section deliv-
eries (Fig. 1). Although most untreated women deliv-
ered at 40 weeks gestation, there was a shift towards
earlier delivery for all treatment groups, but no evi-
dence of an abrupt change. By 37 weeks, 16% of the
untreated, 17% of the monotherapy group, 22% of the
antiretroviral therapy without PI and 29% of the
antiretroviral therapy with PI group had delivered.
From Kaplan±Meier analysis, gestational age at delivery
varied signi®cantly by treatment group (log rank
÷2(3)  129.4; P , 0.001). Overall, birthweight was
appropriate for gestational age. There were no signi®-
cant differences between mean birthweights by treat-
ment group (no/monotherapy versus combination
therapy) for premature infants, with means of 2170 g
and 2233 g respectively (P  0.446).
Table 3. Maternal factors and prematurity.
Premature delivery
Univariate odds ratio Multivariate odds ratio
No (%) Yes (%) (95% CI) (95% CI)
CD4 cell count (3 106 cells/l)
> 500 487 (87) 71 (13) 1.00 1.00
200±499 559 (84) 105 (16) 0.96 (0.76±1.21) NS 1.23 (0.88±1.71)
, 200 176 (78) 49 (22) 1.42 (1.02±1.99) P  0.03 1.93 (1.28±2.91) P , 0.02
÷2  10.1, P  0.006
Injecting drug use during pregnancy
No 2087 (85) 360 (15) 1.00 1.00
Yes 581 (76) 186 (24) 1.86 (1.53±2.27) P , 0.02 2.41 (1.71±3.41) P , 0.02
÷2  37.0, P , 0.001
Antiretroviral therapy in pregnancy
None 2375 (84) 444 (16) 1.00 1.00
Monotherapy 462 (83) 93 (17) 1.08 (0.84±1.38) NS 1.03 (0.70±1.50) NS
Combination therapy: no PI 147 (78) 41 (22) 1.49 (1.04±2.14) P , 0.05 1.82 (1.13±2.92) P , 0.02
Combination therapy: with PI 72 (71) 29 (29) 2.15 (1.38±3.35) P , 0.02 2.60 (1.43±4.75) P , 0.02
÷2  15.9, P  0.001
Adjusted for all other variables in model. CI, con®dence interval; NS, not signi®cant.
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Discussion
These results con®rm the reports from the Swiss
Cohort that antiretroviral therapy in pregnancy, espe-
cially when involving PIs, increases risk of premature
delivery [5]. Preliminary results from a meta-analysis of
PACTG perinatal trials showed no increased risk of
prematurity associated with combination antiretroviral
therapy in pregnancy compared with no treatment or
monotherapy [8]. The discrepancy between this and
our ®ndings may be due to different populations, or
different approaches to analysis. We allow for other
factors known to be associated with length of gestation
in HIV-infected women, including maternal illicit drug
use and immunosuppression and thus substantially in-
crease the reliability of the estimated effect. Maternal
CD4 count was a better predictor of prematurity than
maternal viral load, with severe immunosuppression
independently associated with a doubled risk of preterm
labour. This is consistent with results from other studies
[13,15]. The link between illicit drug use and prema-
turity in both HIV-infected and non-infected pregnant
women is well established [16,17], and was observed
here.
A previous ®nding in the ECS was that zidovudine
monotherapy increased length of gestation but this
effect was only marginally signi®cant [12]. In this larger
combined dataset, two years on, zidovudine monother-
apy no longer had an effect on duration of pregnancy.
However, interestingly, the risk of prematurity in this
group was highest when zidovudine was introduced in
the third trimester. The crude preterm delivery rates
reported here of 17% for women on monotherapy and
16% among those untreated are broadly similar to the
19% rate reported in an American cohort, where one-
third of mothers received zidovudine monotherapy
during pregnancy [18]. However, our crude prematur-
ity rates of 22 and 29% for women on combination
therapy without and with PIs respectively, are higher
than the 20% rate reported in a review of 76 completed
pregnancies in the US in which PIs were taken [19].
The ®nding that women on combination therapy and
receiving treatment when their pregnancy was con-
®rmed had double the risk of premature delivery
compared to those who started therapy within the last
trimester may shed some light on the underlying
mechanisms. The fact that infants' birthweight was
generally appropriate for their gestational age implies an
effect on the mother rather than on uteroplacental
function. The association we report between combina-
tion therapy with PI and prematurity may indicate an
effect of these drug combinations over and above that
on maternal HIV viral load. Further research may be
indicated to explore other pregnancy outcomes, such as
spontaneous abortions, in HIV-infected women on
combination therapy.Ta
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Vertical transmission rates are substantially reduced with
use of elective caesarean section delivery, prophylactic
antiretroviral therapy and formula-feeding [2±4,6,7,
20]. Conversely, prematurity is associated with a two-
to three-times increased risk of mother-to-child trans-
mission [2,20,21]. There may therefore be a smaller
reduction in the overall vertical transmission risk if
increasing numbers of infants of HIV-infected mothers
on combination therapy are born prematurely. How-
ever, our results also suggest that such an effect would
be limited to infants of mothers who started combina-
tion therapy with PI before pregnancy or during the
®rst trimester.
In terms of morbidity and health service needs, degree
of prematurity is more important than whether an
infant is classi®ed as premature or term. There was a
2.5-times increased risk of premature delivery in
women on combination therapy with PIs, and 6% of
their infants were born at less than 32 weeks gestation
(versus approximately 2% for the other groups), when
risk of postnatal problems are greatest [22,23]. The
main implications of our ®ndings relate to management
of pregnancy in women on combination therapy,
notably mode of delivery. Following European guide-
lines [1] all HIV-infected pregnant women should be
offered an elective caesarean section to reduce the
vertical transmission risk [24]. The risk following an
emergency caesarean section is similar to that associated
with vaginal delivery [4,24], although duration of
rupture of membranes is an independent risk factor for
mother-to-child transmission [3,20]. Our ®ndings raise
the question of whether the timing of elective caesar-
ean section for women on combination therapy should
be brought forward. In our cohort, if all women on
combination therapy with PIs were delivered by
elective caesarean section at 36 weeks, an additional
19% of infants would avoid vaginal or emergency
caesarean section delivery. Such a change in practice
would have to be weighed against the risks associated
with earlier gestational age, such as lower birthweight
and increased respiratory morbidity.
An HIV-infected woman of child-bearing age is in the
unique position of making treatment decisions which
will not only impact on her own health, but may also
affect her future children [1,8]. Our ®ndings highlight
the need for health care providers to discuss future
plans with HIV-infected women when deciding what
kind of therapy to initiate. For women keen to start a
family and without clinical or immunological indica-
tions for combination antiretroviral therapy, it may be
prudent to defer starting combination therapy until
after the ®rst trimester of pregnancy.
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